Serina Therapeutics (SER) Non-Current Assets (2017 - 2026)

Serina Therapeutics has disclosed Non-Current Assets across 10 years of filings, most recently posting $784000.0 for Q2 2026.

• In Q2 2026, Non-Current Assets fell 17.47% year-over-year to $784000.0; the TTM figure through Jun 2026 stood at $3.5 million (down 29.4% YoY), while the FY2025 annual figure was $871000.0, down 16.89% from the prior year.
• Non-Current Assets came in at $784000.0 for Q2 2026 at Serina Therapeutics, down from $871000.0 in the prior quarter.
• In the past five years, Non-Current Assets ranged from a high of $11.1 million in Q3 2023 to a low of -$1.2 million in Q1 2023.
• Average Non-Current Assets over 5 years is $1.5 million, with a median of $916000.0 recorded in 2025.
• The largest YoY upside for Non-Current Assets was 1248.23% in 2023 against a maximum downside of 240.92% in 2023.
• Over 5 years, Non-Current Assets stood at $788000.0 in 2022, then surged by 71.19% to $1.3 million in 2023, then declined by 22.31% to $1.0 million in 2024, then dropped by 16.89% to $871000.0 in 2025, then decreased by 9.99% to $784000.0 in 2026.
• Per Business Quant data, the three most recent Non-Current Assets figures were $784000.0 in Q2 2026, $871000.0 in Q4 2025, and $916000.0 in Q3 2025.